Logo 1 Logo 2

Investigational Drug Details

Drug ID: D164
Drug Name: Voriconazole
Synonyms:
Type: small molecule
DrugBank ID: DB00582
DrugBank Description: Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections.
PubChem ID: 71616
CasNo: 137234-62-9
Repositioning for NAFLD: Yes
SMILES: C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
Structure:
InChiKey: BCEHBSKCWLPMDN-MGPLVRAMSA-N
Molecular Weight: 349.3105
DrugBank Targets: Cytochrome P450 51
DrugBank MoA: Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha sterol demethylase. The inhibition of 14-alpha sterol demethylase results in a depletion of ergosterol in fungal cell membrane.
DrugBank Pharmacology: Voriconazole is a triazole antifungal agent indicated for use in the treatment of fungal infections including invasive aspergillosis, esophageal candidiasis, and serious fungal infections caused by <i>Scedosporium apiospermum</i> (asexual form of <i>Pseudallescheria boydii</i>) and <i>Fusarium</i> spp. including <i>Fusarium solani</i>. Fungal plasma membranes are similar to mammalian plasma membranes, differing in having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane permeability changes and inhibition of growth.
DrugBank Indication: For the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by <i>Scedosporium apiospermum</i> and <i>Fusarium</i> spp.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: